NEW YORK, June 10-Exelixis subsidiary Artemis Pharmaceuticals has struck a deal with Merck to create customized mouse models of disease, the company said today.
Merck will provide genetic specifications for the mice, and Artemis will use its gene inactivation technology to develop the strains.
The companies did not disclose financial details of the agreement.
Exelixis acquired Cologne, Germany-based Artemis in 2001.
For more details, see the company website.